Immunophotonics CEO Lu Alleruzzo announced, along with Dr. Robert CG Martin II, M.D, PhD, PACS, who serves as the Principal Investigator and National Coordinating Investigator at the University of Louisville, that the first patient has been dosed with IP-001 in the United States under Immunophotonics’ Investigational New Drug (IND) application with the FDA. The U.S. trial sites will play a key role in this multi-national trial and will join other sites in France, Germany, Switzerland, and the United Kingdom that are already enrolling patients for treatment of colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma.

Read more: (Official Press Release)